Sales in Connelly’s $11 billion unit were flat in 2012, but she outperformed GSK, which saw revenue decline 4.6%. Recent FDA approvals could help revive sales; GSK has the go-ahead on meds to combat chronic obstructive pulmonary disease, a leading cause of death in the U.S.